



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

637.MYELODYSPLASTIC SYNDROMES - CLINICAL AND EPIDEMIOLOGICAL

Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Sankalp Arora, MBBS¹, Jayastu Senapati, MDMBBS,DM², Naveen Pemmaraju, MD², Prithviraj Bose, MD³, Lucia Masarova, MD², Guillermo Montalban-Bravo, MD², Abhishek Maiti, MD⁴, Tapan M. Kadia, MD², Elias Jabbour, MD⁵, Guillermo Garcia-Manero, MD⁶, Hagop M. Kantarjian, MD², Naval Daver, MD²

¹ Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

³ MD Anderson Cancer Center, Houston, TX

⁴ Department of Leukemia, MD Anderson Cancer Center, Houston, TX

⁵ University of Texas M.D. Anderson Cancer Ctr., Houston, TX

⁶ University of Texas MD Anderson Cancer Center, Houston, TX

Introduction:

MDS/MPN represent a distinct category of Philadelphia chromosome negative myeloid neoplasms that share pathological and morphological characteristics with both MDS and MPN. Very few prospective studies have been conducted in pts with MDS/MPN, with currently available data showing a median overall survival (OS) of less than two years in this challenging subset. We conducted a phase 2 clinical trial evaluating the combination of JAK-inhibitor RUX with demethylating agent AZA in pts with MDS/MPN. The interim analyses (Assi et al, AJH 2018) showed objective responses in 57% pts and a median duration of response (DOR) of 8 months (mos). Herein we report the long-term follow up of a larger cohort of pts treated on this prospective ongoing clinical trial.

Methods:

We conducted an open label single-arm phase 2 clinical trial (NCT01787487) at the MD Anderson Cancer Center, Houston, evaluating the use of RUX-AZA in newly diagnosed or previously treated MDS/MPN. Adults aged ≥ 18 years with MDS/MPN categorized as Intermediate 1-2 or High-risk by Dynamic International Prognosis Scoring System (DIPSS) (Passamonti et al, Blood 2010) were included. Pts previously exposed to RUX and/or AZA were excluded. RUX 5-20mg twice daily (per RUX label depending upon platelet counts at initiation) was given in 28-day cycles, and AZA 25mg/m² (SQ or IV) Days 1- 5 was added starting cycle 4. Cycles were repeated every 4-6 weeks depending on count recovery. Response assessment was carried out using the 2015 International Consortium Proposal of response MDS/MPN criteria (Savona M et al, Blood 2015) and best objective response was tabulated. Progression free survival (PFS) included treatment change because of disease progression or inadequate response, transformation to acute myeloid leukemia (AML) or death and calculated from the time of therapy initiation.

Results:

From May 2013 to August 2022, 52 pts with a median age of 68 years (range, 39-82 years) were treated on trial. The data cutoff was July 15, 2023 (**Table 1**). 32 pts (61%) were males, and 9 (75%) pts were white. 50 pts (96%) had ECOG PS \leq 2. Baseline median bone marrow (BM) blasts were 4.5% (range 0-19%), with 19 (37%) carrying JAK2 mutations, and 16 (31%) with an abnormal karyotype. Intermediate-2 DIPSS was the most prevalent risk category, seen in 23 (44%) pts. At least one cytopenia was present in 32 (61%) pts, and three (6%) pts had bicytopenia. 24 of 49 (49%) had palpable splenomegaly, and 3 pts had undergone prior splenectomy. After a median follow up of 60 months (mos) (95% CI: 50.0-71.3) from therapy initiation, 18 (35%) pts are alive, and 1 pt is on active trial therapy. Objective responses per the MDS/MPN international consensus response criteria were observed in 28 (54%) pts and included clinical improvement in 14 (50%) pts, partial marrow response in 12 (43%) pts, optimal marrow response and cytogenetic complete remission in 1 (4%) pt each. The DOR in the 28 pts with objective response to therapy (censored for death in pts who died without evidence of progression) was 35 mos (95% CI: NE-73.5). The median OS in this group of responders was 36.4 mos (95% CI: NE-77.2). Five of these pts died without confirmed disease progression at the time of death. For the full cohort the median PFS was 13.4 mos (95% CI: 7.9-18.8) and median OS was 31.8

mos (95% CI: 18.5-44.9) (**Figure 1**). Transformation to AML occurred in 12 (23%) pts, with the median time to transformation being 13.2 mos (range 2.9-71.3) and all of them have died at the time of last follow-up. 8 (15%) pts underwent allogeneic stem cell transplant (ASCT) as subsequent therapy following treatment with AZA-RUX amongst whom 6 (75%) had shown objective responses prior to transplant. For the pts who underwent ASCT, median PFS from the initiation of AZA-RUX was 40.8 months and median OS was not reached.

Conclusion:

Long term follow up from this phase II prospective clinical trial demonstrates durable disease responses with the RUX-AZA combination in MDS/MPN, with the responses translating into improved survival outcomes.

Disclosures Senapati: Kite Pharma: Other: Advisory Board. **Pemmaraju:** ClearView Healthcare Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Imedex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Protagonist Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; EUSA Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Curio Science: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; CareDx: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Harborside Press: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dava Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CancerNet: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Aplastic Anemia & MDS International Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pacylex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Patient Power: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; United States Department of Defense (DOD): Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PeerView Institute for Medical Education: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Medscape: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; OncLive: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Physician Education Resource (PER): Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASH Committee on Communications: Other: Leadership; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Magdalen Medical Publishing: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Karger Publishers: Other: Licenses; Intellisphere: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASCO Cancer.Net Editorial Board: Other: Leadership; Blueprint: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cimeio Therapeutics AG: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ImmunoGen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Aptitude Health: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; HemOnc Times/Oncology Times: Other: Uncompensated; Bristol Myers Squibb Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Bose:** Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo: Honoraria, Research Funding; Kartos, Telios, Ionis, Disc, Janssen, Geron: Research Funding; GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic: Honoraria. **Masarova:** MorphoSys US: Membership on an entity's Board of Directors or advisory committees. **Montalban-Bravo:** Rigel: Research Funding; Takeda: Research Funding. **Maiti:** Celgene: Research Funding; Lin BioScience: Research Funding. **Kadia:** Cure: Speakers Bureau; Biologix, Cure, Hikma Pharmaceuticals: Speakers Bureau; Sanofi-Aventis: Consultancy; Regeneron Pharmaceuticals: Research Funding; Hikma Pharmaceuticals: Speakers Bureau; Cellenkos Inc.: Research Funding; SELLAS Life Sciences Group: Research Funding; AbbVie, Amgen, Inc, Ascentage Pharma Group, Astellas Pharma Global Development, Astex, AstraZeneca, BMS, Celgene, Cellenkos Inc, Cyclacel, Delta-Fly Pharma, Inc, Genentech, Inc., Genfleet, Glycomimetics, Iterion, Janssen Research and Development: Research Funding; Genzyme: Honoraria; Novartis: Consultancy; Genentech: Consultancy, Research Funding; Delta-Fly Pharma, Inc.: Research Funding; Jazz Pharmaceuticals, Pfizer, Pulmotect, Inc, Regeneron Pharmaceuticals, SELLAS Life Sciences Group: Research Funding; Amgen, Inc.: Research Funding; Ascentage Pharma Group: Research Funding; Iterion: Research Funding; Liberum: Consultancy; Glycomimetics: Research Funding; Agios: Consultancy; Daiichi Sankyo, Genentech, Inc., Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Inc, Pulmotect, Inc, Sanofi-Aventis, Servier: Consultancy; Celgene: Research Funding; AstraZeneca: Research Funding; Pfizer: Consultancy, Research Funding; GenFleet Therapeutics: Research Funding; Janssen Research and Development: Research Funding; Astellas Pharma Global Development: Research Funding;

Cyclacel: Research Funding; *Pulmotect, Inc.*: Consultancy, Research Funding; *Servier*: Consultancy; *Pinotb-Bio*: Consultancy; *BMS*: Consultancy, Research Funding; *Astex*: Honoraria. **Jabbour**: *Adaptive Biotech*: Consultancy, Honoraria, Research Funding; *Abbvie*: Consultancy, Honoraria, Research Funding; *Amgen*: Consultancy, Honoraria, Research Funding; *Pfizer*: Consultancy, Honoraria, Research Funding; *Takeda*: Consultancy, Honoraria, Research Funding; *Genentech*: Consultancy, Honoraria, Research Funding; *Ascentage Pharma Group*: Consultancy, Honoraria, Research Funding; *Bristol-Myers Squibb*: Consultancy, Honoraria, Research Funding; *Hikma Pharmaceuticals*: Consultancy, Honoraria, Research Funding. **Garcia-Manero**: *Genentech*: Research Funding; *Bristol Myers Squibb*: Other: Medical writing support, Research Funding; *AbbVie*: Research Funding. **Daver**: *Astellas*: Consultancy, Research Funding; *AROG*: Consultancy; *Syndax*: Consultancy; *AbbVie*: Consultancy, Research Funding; *Shattuck Labs*: Consultancy; *Trovagene*: Research Funding; *Agios*: Consultancy; *Genentech*: Consultancy, Research Funding; *Hanmi*: Research Funding; *Gilead*: Consultancy, Research Funding; *Glycomimetics*: Research Funding; *Novimmune*: Research Funding; *FATE*: Research Funding; *Celgene*: Consultancy; *Daiichi Sankyo*: Consultancy, Research Funding; *Amgen*: Consultancy, Research Funding; *ImmunoGen*: Consultancy, Research Funding; *Novartis*: Consultancy; *Bristol-Myers Squibb*: Consultancy, Research Funding; *Trillium*: Consultancy, Research Funding; *Jazz*: Consultancy; *Kite, a Gilead company*: Consultancy, Research Funding; *Pfizer*: Consultancy, Research Funding; *Servier*: Consultancy, Research Funding; *Kronos Bio*: Research Funding.

Parameters		N (%), [range]
Age (years)	Median Age	68 [34-84]
	Range	47-83
Gender	Males	32 (62)
Race	White	26 (50)
Performance Status	ECOG PS<2	50 (96)
Clinical Response (n=50)	Response	35/48 (73%)
	Non-response	13 (27%)
Baseline blood and BM	Hb (g/dl)	9.8 [6.1-14.4]
	WBC (10 ⁹ /L)	21.7 [2.2 - 123.2]
	Platelet (10 ⁹ /L)	169 [53-1429]
	LDH (IU)	758 [203-3615]
	BM blasts (%)	4.5 [0-19]
Immunophenotype (n=50)	CD3	24 (48%)
	CD4	26 (52%)
	CD8	6 (12%)
	CD45	26 (52%)
	CD56	2 (4%)
Cytogenetics	Diploid	36 (69)
	Complex	4 (8)
	Other abnormal karyotypes	12 (23)
	del 5q	1
	del 7q	1
	+8	2
Immunoglobulin gene	IGH	25 (50%)
	IGK	26 (52%)
	IGD	2 (4%)
	IGL	2 (4%)
	IGHG	26 (52%)
	IGHA	26 (52%)
	IGHJ	26 (52%)
DIPSS	Low	0 (0)
	Int-1	12 (23)
	Int-2	23 (44)
	High	17 (33)

Abbreviations: ECOG Eastern Cooperative Oncology Group, PS, Performance Status; BM, Bone Marrow; WBC, White Blood Cell; LDH, Lactate Dehydrogenase; IGH, Immunoglobulin Heavy Chain; IGK, Immunoglobulin Light Chain; IGD, Immunoglobulin D; IGL, Immunoglobulin Light Chain; IGHG, Immunoglobulin Heavy Chain Gamma; IGHA, Immunoglobulin Heavy Chain Alpha; IGHJ, Immunoglobulin Heavy Chain Joining; IGHK, Immunoglobulin Heavy Chain Joining; IGLK, Immunoglobulin Light Chain Joining; IGLJ, Immunoglobulin Light Chain Joining.

*These patients had prior splenectomy

**These patients did not have clonal geneing confirmed on the marrow sample

Legend: In solid line, 100% of the patients




Figure 1

<https://doi.org/10.1182/blood-2023-187035>